长脉宽与短脉宽胼胝体下扣带回刺激治疗难治性抑郁:随机双盲交叉试验
这项在加拿大卡尔加里开展的随机双盲交叉试验纳入22例难治性抑郁患者,比较短脉宽(90 μs)与长脉宽(210-450 μs)胼胝体下扣带回深部脑刺激的疗效与安全性。6个月时两组HDRS评分均显著下降且组间无差异,交叉阶段组内与组间均无显著变化,不良事件两组相当。
要点
- 短脉宽与长脉宽刺激在6个月时均显著降低HDRS评分,组间无差异。
- 交叉阶段(6-12个月)组内与组间HDRS变化均不显著。
- 两组不良事件相当,常见为焦虑和抑郁加重,短脉宽组1例自杀死亡。
核心结论
- 长脉宽与短脉宽胼胝体下扣带回白质束刺激风险相似,降低抑郁症状疗效相当,提示脉宽与电压滴定均可能优化难治性抑郁的临床结局。
研究设计与样本
- 研究为在加拿大卡尔加里学术医院开展的双盲随机交叉试验,纳入22例DSM-IV重性抑郁障碍或双相抑郁患者(20-70岁,男女均有,治疗无反应超过1年,入组时HDRS-17≥20)。
- 患者接受双侧胼胝体下扣带回白质DBS植入(扩散张量成像纤维束成像),按1:1随机分配至短脉宽(90 μs)或长脉宽(210-450 μs)刺激6个月。
- 频率固定130 Hz,根据HDRS反应每月增加脉宽或电压;6个月未达反应(HDRS较基线降低<50%)者交叉至另一刺激方案再治疗6个月;所有患者接受12周个体化认知行为治疗。
主要发现
- 6个月随机化阶段HDRS评分显著下降(p<0·0001),短脉宽组与长脉宽组间无差异(p=0·54)。
- 交叉阶段6-12个月组内HDRS下降不显著(p=0·15),组间亦不显著(p=0·21)。
- 不良事件两组相等,最常见的心理不良事件为焦虑和抑郁加重;短脉宽组1例患者自杀死亡。
关键数值与推荐
- 入组标准:DSM-IV重性抑郁障碍或双相抑郁,20-70岁,治疗无反应超过1年,入组时HDRS-17评分≥20。
- 主要结局为6个月和12个月时HDRS变化,采用意向性分析。
- 反应定义:HDRS较基线降低≥50%;未达反应者交叉。
临床怎么用
- 对于难治性抑郁接受胼胝体下扣带回DBS的患者,短脉宽与长脉宽刺激均可考虑,两者疗效与安全性相似。
- 临床中可根据HDRS反应每月调整脉宽或电压,频率可维持130 Hz。
- 需监测焦虑、抑郁加重及自杀风险,两组不良事件相当。
局限性
- 样本量小(随机22例),可能限制统计效能与组间差异的检出。
- 交叉阶段组内与组间HDRS变化均不显著,可能受交叉设计及样本量影响。
- 研究在单一学术中心开展,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stimulation adjustment is required to optimise outcomes of deep brain stimulation (DBS) for treatment-resistant depression, but controlled data for ideal stimulation parameters are poor or insufficient. We aimed to establish the efficacy and safety of short pulse width (SPW) and long pulse width (LPW) subcallosal cingulate DBS in depression. METHODS: We did a double-blind, randomised, crossover trial in an academic hospital in Calgary, AB, Canada. Patients had DSM IV-defined major depressive disorder and bipolar depression (20-70 years old, both sexes) and did not respond to treatment for more than 1 year, with a score of 20 or more on the 17-item Hamilton Depression Rating Scale (HDRS) at recruitment. Patients underwent bilateral DBS implantation into the subcallosal cingulate white matter using diffusion tensor imaging tractography. Patients were randomly assigned 1:1 without stratification using a computerised list generator to receive either SPW (90 μs) or LPW (210-450 μs) stimulation for 6 months. Patients and the clinician assessing outcomes were masked to the stimulation group. Keeping frequency constant (130 Hz), either pulse width or voltage was increased monthly, based on response using the HDRS. Patients who did not respond to treatment (<50% reduction in HDRS from baseline) at 6 months crossed over to the opposite stimulation for another 6 months. All patients received individualised cognitive behavioural therapy (CBT) for 12 weeks. The primary outcome was change in HDRS at 6 months and 12 months using intention-to-treat analysis. This study is registered with ClinicalTrials.gov, NCT01983904. FINDINGS: Between Dec 5, 2013, and Sept 30, 2016, of 225 patients screened for eligibility, 23 patients were selected for DBS surgery. After one patient withdrew, 22 (mean age 46·4 years, SEM 3·1; 10 [45%] female, 12 [55%] male) were randomly assigned, ten (45%) to LPW stimulation and 12 (55%) to SPW stimulation. Patients were followed up at 6 months and 12 months. There was a significant reduction in HDRS scores (p<0·0001) with no difference between SPW and LPW groups (p=0·54) in the randomisation phase at 6 months. Crossover groups did not show a significant decrease in HDRS within groups (p=0·15) and between groups (p=0·21) from 6-12 months. Adverse events were equal between groups. Worsening anxiety and depression were the most common psychological adverse events. One patient in the SPW group died by suicide. INTERPRETATION: Both LPW and SPW stimulation of subcallosal cingulate white matter tracts carried similar risks and were equally effective in reducing depressive symptoms, suggesting a role for both pulse width and amplitude titration in optimising clinical outcomes in patients with treatment-resistant depression. FUNDING: Alberta Innovates Health Solutions.
引用
- Ramasubbu R, Clark DL, Golding S, et al. Long versus short pulse width subcallosal cingulate stimulation for treatment-resistant depression: a randomised, double-blind, crossover trial. Lancet Psychiatry. 2020. PMID: 31860455. doi:10.1016/S2215-0366(19)30415-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。